ADC and Immune Checkpoint Combination Therapies

ADCs in combination offer a multifaceted strategy for tackling cancer, providing new avenues for treatment and addressing some of the challenges associated with single-agent therapies. The evolving landscape of combination therapies underscores the importance of ongoing research and clinical trials.

Comparing the new combination trials studying ADCs with chemotherapies and immune checkpoint modulators (ICMs) shows that the combination with ICMs has observed a strong uptrend in the last two years.